VIA
IBRX icon

Vident Investment Advisory’s ImmunityBio IBRX Stock Holding History

Vident Investment Advisory’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-107,144
Closed -$195K – 1255
2023
Q1 		$195K Sell
107,144
-2,954
-3% -$9.19K 0.01% 1109
2022
Q4 		$558K Sell
110,098
-85,029
-44% -$467K 0.02% 670
2022
Q3 		$969K Sell
195,127
-20,846
-10% -$95K 0.03% 601
2022
Q2 		$804K Buy
215,973
+14,385
+7% +$57.8K 0.02% 699
2022
Q1 		$1.13M Buy
201,588
+33,112
+20% +$203K 0.03% 640
2021
Q4 		$1.02M Buy
168,476
+70,722
+72% +$531K 0.03% 697
2021
Q3 		$952K Sell
97,754
-6,982
-7% -$76.8K 0.03% 695
2021
Q2 		$1.5M Buy
+104,736
New +$1.73M 0.05% 521
2018
Q2 		– Sell
-359,420
Closed -$1.45M – 935
2018
Q1 		$1.45M Buy
359,420
+97,406
+37% +$427K 0.06% 344
2017
Q4 		$1.18M Buy
262,014
+75,201
+40% +$356K 0.05% 357
2017
Q3 		$1.02M Buy
186,813
+5,661
+3% +$34.9K 0.06% 365
2017
Q2 		$1.38M Buy
181,152
+42,461
+31% +$183K 0.11% 286
2017
Q1 		$492K Buy
138,691
+23,112
+20% +$114K 0.05% 333
2016
Q4 		$661K Buy
115,579
+13,732
+13% +$91.6K 0.08% 320
2016
Q3 		$792K Sell
101,847
-653
-0.6% -$4.88K 0.11% 310
2016
Q2 		$638K Buy
102,500
+12,056
+13% +$93.6K 0.09% 347
2016
Q1 		$744 Buy
90,444
+42,208
+88% +$398K 0.05% 360
2015
Q4 		$836K Buy
+48,236
New +$716K 0.11% 325

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Vident Investment Advisory's IBRX Position: Q2 2023 in Review

Vident Investment Advisory sold out of ImmunityBio (IBRX) in Q2 2023, closing a stake of 107,144 shares — an estimated $195K sold.

Vident Investment Advisory first reported a position in IBRX in Q4 2015 and held it in 18 quarters. The position peaked at $1.5M in Q2 2021. 117 funds tracked by Wall St. Rank hold IBRX as of Q2 2023.

  • Vident Investment Advisory reported no remaining ImmunityBio position as of Q2 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 107,144 ImmunityBio shares in Q2 2023, an estimated $195K.
  • Vident Investment Advisory first reported a position in ImmunityBio in Q4 2015 and held it in 18 quarters.
  • Vident Investment Advisory's ImmunityBio position peaked at $1.5M in Q2 2021.
  • 117 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2023.

Based on Vident Investment Advisory's 13F filing for Q2 2023, filed 11 Aug 2023.